Страна 1 од 49 резултати
FIELD OF THE INVENTION
The present invention relates to the area of chemotherapeutic agents and, more particularly, relates to certain substituted caprolactam carbonates and ethers, and the use of said caprolactam carbonates and ethers in treating tumors.
BACKGROUND OF THE INVENTION
Cancer is a
FIELD OF THE INVENTION
The present invention relates to the area of chemotherapeutic agents and, more particularly, relates to certain substituted caprolactam carbonates and ethers, and the use of said caprolactam carbonates and ethers in treating tumors.
BACKGROUND OF THE INVENTION
Cancer is a
FIELD OF THE INVENTION
The invention relates to nordihydroguaiaretic acid derivatives particularly useful for treating viral infections and tumors.
BACKGROUND
Nordihydroguaiaretic acid (NDGA, 1) is a lignan found in the leaves and twigs of the shrub Larrea tridentata. Being a lipoxygenases
FIELD OF THE INVENTION
The invention relates to nordihydroguaiaretic acid derivatives particularly useful for treating viral infections and tumors.
BACKGROUND
Nordihydroguaiaretic acid (NDGA, 1) is a lignan found in the leaves and twigs of the shrub Larrea tridentata. Being a lipoxygenases
BACKGROUND OF THE INVENTION
The delivery of RNAi triggers and other substantially cell membrane impermeable compounds into a living cell is highly restricted by the complex membrane system of the cell. Drugs used in antisense, RNAi, and gene therapies are relatively large hydrophilic polymers and
FIELD OF THE INVENTION
This invention relates generally to compositions and methods useful in the prevention and treatment of osteoporosis and for bone and fracture repair. More specifically, the invention relates to slow-releasing calcium phosphate-based materials incorporating Mg, Zn, F, carbonate
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to a method for improving the recovery of cesium-131 (Cs-131) from barium (Ba). Uses of the Cs-131 purified by the method include cancer research and treatment, such as for use in brachytherapy implant
BACKGROUND OF THE INVENTION
In recent years, cancer has become, of the major diseases, a most serious threat to human health. The World Health Organization (WHO) 2008 statistics show that the global number of cancer deaths worldwide is about 11 million new cases of cancer each year, with the
TECHNICAL FIELD
The invention relates to a biodegradable polymer material and its application, in particular to a carbonate polymer containing a functional group of disulfide five-membered ring in the side chain and its application, belonging to the field of medical material.
BACKGROUND
FIELD OF THE INVENTION
The present invention relates to the provision of a composition for use in the prevention and/or treatment of colorectal cancer comprising a) a multi-kinase inhibitor; and b) at least one chemotherapeutic agent. Furthermore, the present invention also discloses a
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn.371 and claims the priority of International Patent Application No. PCT/EP2015/061641, filed on 27 May 2015 entitled "ANTITUMOR ACTIVITY OF MULTI-KINASE INHIBITORS IN TRIPLE NEGATIVE BREAST
TECHNICAL FIELD
The present invention pertains to the field of medicine, and relates to spirocyclic indolone polyethylene glycol carbonate compounds, and compositions thereof, to processes for their preparation, and to the use thereof as anticancer drugs due to their antitumor
TECHNICAL FIELD
The present invention relates to a potentiating agent that potentiates the antitumor effect of an anticancer agent. The present invention also relates to a kit for treating cancer and an agent for treating cancer employing the potentiating agent.
BACKGROUND ART
Despite a recent
FIELD OF THE INVENTION
This invention relates to the use of 2'-fluoro-5-methyl-.beta.-L-arabinofuranosyluridine (LFMAU or clevudine) or its related analog, .beta.-L-2'-deoxyribofuranosylthymidine (L-deoxythymidine, LDT, L-dT or telbivudine) or conjugates comprising these agents alone or along with
FIELD OF THE INVENTION
This invention relates to the use of 2'-fluoro-5-methyl-.beta.-L-arabinofuranosyluridine (LFMAU or clevudine) or its related analog, .beta.-L-2'-deoxyribofuranosylthymidine (L-deoxythymidine, LDT, L-dT or telbivudine) or conjugates comprising these agents alone or along with